| Document |
Document Title |
|
WO/2024/071509A1 |
The present invention may provide a pharmaceutical composition for the prevention or treatment of Alzheimer's disease, the composition containing: an amyloid-beta peptide or a nucleic acid encoding same; and rapamycin or a derivative the...
|
|
WO/2024/071566A1 |
An electronic device according to an example may comprise: a cartridge accommodating part for accommodating a cartridge including an emulsion therein; a crushing circuit including a crushing element capable of crushing at least a portion...
|
|
WO/2024/072794A1 |
The invention provides pyridine carboxamide compounds, pharmaceutical compositions, and their use in treating medical conditions.
|
|
WO/2024/072870A1 |
Quinoline compounds are disclosed that have a formula represented by the following: and wherein Cy, R1, R4a, R4b, and n are as described herein. The compounds may be prepared as compositions, e g., pharmaceutical compositions, or as dosa...
|
|
WO/2024/068010A1 |
A first aspect of the invention relates to a nucleic acid agent capable of downregulating or inhibiting the expression or biological activity of SNX9 in a target cell, wherein the nucleic acid agent is selected from an antisense oligodeo...
|
|
WO/2024/067566A1 |
Provided are a following compound (I), or a pharmaceutically acceptable salt, an ester, an optical isomer, a tautomer, a stereoisomer, a polymorph, a solvate, an N-oxide, an isotope-labeled compound, a metabolite, a chelate, a complex, a...
|
|
WO/2024/067857A1 |
A macrocyclic derivative. Specifically disclosed are a compound represented by formula (VI), a stereoisomer thereof, and a pharmaceutically acceptable salt thereof.
|
|
WO/2024/073762A2 |
Disclosed herein are compositions comprising a long chain alcohol comprising octacosanol, hexacosanol, and/or tricontanol in an amount of at least 50% by weight based on total weight of the long chain alcohol; a cannabinoid; and a carrie...
|
|
WO/2024/069613A1 |
A composition containing a therapeutically effective amount of a cannabinoid for the treatment of temporomandibular disorders (TMD) that include temporomandibular joint (TMJ) pain.
|
|
WO/2024/069576A1 |
Novel crystalline forms of 1-(8-bromopyrido[2,3-e][1,2,4]triazolo[4,3-a]pyrazin-4-yl)-N
- methylazetidin-3-amine 1-(8-bromopyrido[2,3-e][1,2,4]triazolo[4,3-a]pyrazin-4-yl)-N
- methylazetidin-3-amine mono succinate is provided along with ...
|
|
WO/2024/073642A1 |
Described are gummy dosage forms comprising tricalcium phosphate and a relaxing ingredient selected from Lemon balm extract, L-theanine, GABA, or mixtures thereof.
|
|
WO/2024/071959A1 |
The present invention relates to a method for synthesizing a derivative obtained by esterifying choline alfoscerate. The present invention also relates to a preparation comprising a choline alposcerate ester (TGPC) derivative and a use t...
|
|
WO/2024/067304A1 |
The present invention provides a compound with inhibitory activity against Sigma2 and 5HT2A. The compound can be used as a dual-target inhibitor of Sigma2 and 5HT2A for the treatment of a related disease mediated by Sigma2 receptor activ...
|
|
WO/2024/073732A1 |
One aspect of the present disclosure relates to a dsRNA agent comprising a sense strand and an antisense strand sufficiently complementary to at least one portion of a mRNA of the target gene, each strand having 14 to 40 nucleotides, whe...
|
|
WO/2024/067694A1 |
The present invention relates to a nitrogen-containing heterocyclic compound and pharmaceutical use thereof. Specifically, the present invention relates to a nitrogen-containing heterocyclic compound represented by general formula (I), a...
|
|
WO/2024/072110A1 |
The present invention relates to a novel tricyclic heterocyclic carbaldehyde compound and a pharmaceutical composition, containing same, for IRE1α inhibition and, more specifically, to a novel tricyclic heterocyclic carbaldehyde compoun...
|
|
WO/2024/067302A1 |
The present invention provides an amide compound, which has inhibitory activity against the Sigma2 receptor and 5HT2A receptor and can be used as a dual-target inhibitor of Sigma2 and 5HT2A for the treatment of a related disease mediated...
|
|
WO/2024/072079A1 |
The present invention relates to a pharmaceutical composition for preventing or treating cardiovascular aging diseases, comprising enavogliflozin as an active ingredient. Enavogliflozin of the present invention exhibits excellent effects...
|
|
WO/2024/067477A1 |
Disclosed herein are an anti-CD33 antibody and an anti-CD33 antibody-drug conjugate and use thereof. Specifically disclosed are an anti-CD33 antibody and/or an antigen-binding fragment thereof, a pharmaceutical composition comprising an ...
|
|
WO/2024/067676A1 |
Provided are a compound represented by general formula (1), a preparation method therefor, and use of the compound represented by general formula (1) and isomers, crystal forms, pharmaceutically acceptable salts, hydrates or solvates the...
|
|
WO/2024/073758A1 |
Provided herein, inter alia, are hydrogel composite, its compositions, and use thereof for treatment of undesired adhesion formation and treatment of peripheral nerves, e.g., by preventing scarring and adhesion of peripheral nerves.
|
|
WO/2023/230286A9 |
Disclosed herein is a method of treating lymphoma by administering 8-cyclopentyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-
oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile or a pharmaceutically-acceptable salt thereof, alone or...
|
|
WO/2024/071393A1 |
The present invention provides a compound having an excellent control effect on harmful arthropods. A compound represented by formula (I) [wherein the meaning of each symbol is as described in the description] or N-oxide thereof has an e...
|
|
WO/2024/067811A1 |
Provided herein are compounds having formulas (I) or (VII) or pharmaceutically acceptable salts, tautomers, isotopologues, stereoisomers, or prodrugs thereof; ligand-drug conjugates and pharmaceutically acceptable salts or solvates there...
|
|
WO/2024/073733A2 |
The present disclosure provides, in part, methods of eliciting immuno-tolerance using truncated membrane-bound and soluble immune checkpoints. Constructs comprising the immune checkpoint protein or portions thereof capable of binding to ...
|
|
WO/2024/067722A1 |
Provided are a patch comprising colchicine and a preparation method therefor and use thereof, wherein the patch comprises a polymer matrix layer. The polymer matrix layer comprises the following components in percentage by weight: 0.1%-5...
|
|
WO/2024/072334A1 |
The present invention relates to the use of borate derivatives in the treatment of amyotrophic lateral sclerosis (ALS), which is a neurodegenerative disease. More particularly, it relates to the development and administration of pharmace...
|
|
WO/2024/069050A1 |
The invention relates to co-administration a CYP2D6 inhibitor with tasipimidine, or a pharmaceutically acceptable salt thereof, in order to improve the pharmacokinetic profile of tasipimidine by decreasing its clearance and inter-individ...
|
|
WO/2024/073756A2 |
A composition, a method for selectively altering expression of a gene, and a method of selectively modulating activity of a Cas protein is provided. The composition includes a nucleotide regulator wherein the regulator is an oligonucleot...
|
|
WO/2024/067575A1 |
Disclosed are a nitrogen-containing polycyclic compound, and a pharmaceutical composition and use thereof. The nitrogen-containing polycyclic compound of the present invention is a nitrogen-containing polycyclic compound represented by f...
|
|
WO/2024/067844A1 |
The present application provides a crystal A of fexuprazan hydrochloride. An X-ray powder diffraction pattern thereof has characteristic peaks at positions of 2θvalues of 9.1±0.2°, 13.7±0.2°, 14.9±0.2° and 18.3±0.2°, and has a c...
|
|
WO/2024/073334A1 |
Provided herein are methods of combined treatments using bupropion and/or its metabolites and zonisamide or other similar anticonvulsants or GABAergic agents, optionally in further combination with one or more nicotine replacement or sub...
|
|
WO/2024/068386A1 |
The PDE4-inhibitor of formula A' A', for use in a method for the treatment of a progressive fibrosing interstitial lung disease (PF-ILD), preferably IPF, in a patient comprising the following steps: a) measuring or having measured the co...
|
|
WO/2024/073426A1 |
Provided dihydroquinazolinone and azadihydroquinazolinone compounds for treating cardiac indications such as hypertrophic cardiomyopathy and diastolic dysfunction.
|
|
WO/2024/069007A2 |
The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer, diastereoisomer, enantiomer, polymorph, racemic mixture, solvate or isomers and mixtures thereof. The invention further relat...
|
|
WO/2024/067745A1 |
The present invention provides a compound slow-release implant of Naltrexone and Risperidone, a preparation method therefor, and use thereof, and relates to the technical field of implant preparation. The compound slow-release implant of...
|
|
WO/2024/072109A1 |
The present invention relates to a co-crystal of enavogliflozin. The enavogliflozin co-crystal of the present invention increased the solubility of enavogliflozin in artificial gastric fluid and artificial intestinal fluid. This improvem...
|
|
WO/2024/072288A1 |
The present invention is directed to processes for obtaining phrgamalin derivatives e.g. of formula la from Entandrophragma caudatum seed extracts,formula (1a) and producing therapeutically active limonoids and limonoid-type compounds su...
|
|
WO/2024/068747A1 |
The present invention relates to a Bifidobacterium longum transitional microorganism for use in preventing and/or reducing the risk of an infection in an infant or young child.
|
|
WO/2024/068926A1 |
The present invention relates to compounds and pharmaceutical compositions comprising the same for the treatment, amelioration and/or prevention of disease. In some embodiments, the disease is a bacterial infection. In some embodiments, ...
|
|
WO/2024/071594A1 |
The present invention relates to a composition comprising a quinazoline salt compound represented by the following chemical formula 1 for treatment of arthritis: [Chemical formula 1] (in chemical formula 1, A is HCl, HClO3, H2SO4, HNO3, ...
|
|
WO/2024/067783A1 |
Provided are a compound represented by formula (I), an optical isomer thereof, or a pharmaceutically acceptable salt thereof, and use of the compound as an androgen receptor (AR) inhibitor.
|
|
WO/2024/071360A1 |
The purpose of the present invention is to clarify the effects of NMN on infants. The invention addresses the problem of providing a composition capable of promoting brain function development in infants. Provided is a composition for pr...
|
|
WO/2024/067327A1 |
The present invention relates to use of a triterpenoid saponin compound with a general formula structure represented by formula A in the preparation of a medicament for preventing and/or treating nodule, fibrosis, or granuloma diseases, ...
|
|
WO/2024/072778A1 |
Provided herein are methods of treating at least one symptom of ALS in a subject, the method comprising administering to a subject who has received an inhibitor of a transporter a first dosage of a composition comprising TURSO and sodium...
|
|
WO/2024/072352A1 |
The present invention relates to injectable smart hydrogels that are sensitive to temperature and light and with increased mechanical properties and which can be used in the biomaterial technical field, particularly in controlled drug re...
|
|
WO/2024/069592A1 |
The present application discloses specific compounds of Formula (I) and their use in therapy, in particular, their use as Polymerase Theta (Polθ) inhibitors for the treatment of cancer. The application further discloses the use of a com...
|
|
WO/2024/073328A2 |
The present invention provides a method of treating cancer in a subject in need thereof, comprising administering to the subject Compound 1 (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising Com...
|
|
WO/2024/067792A1 |
The present disclosure provides a compound represented by formula (I) or a pharmaceutically acceptable salt, a pharmaceutical composition comprising the same, and use of the same, particularly suitable for preparing a drug for treating o...
|
|
WO/2024/067781A1 |
The present invention relates to a pharmaceutically acceptable salt and a crystal form of a tetrahydronaphthalene derivative, and a preparation method. Specifically, the present disclosure provides a pharmaceutically acceptable salt and ...
|
